# SLC16A3

## Overview
SLC16A3 is a gene that encodes the protein monocarboxylate transporter 4 (MCT4), a member of the solute carrier family 16. MCT4 is a transmembrane protein that plays a critical role in the transport of monocarboxylates, such as lactate and pyruvate, across the plasma membrane. This transporter is particularly important in tissues with high glycolytic activity, such as white skeletal muscle fibers, astrocytes, and certain tumor cells, where it facilitates the efflux of lactic acid produced during glycolysis. The protein's structure is characterized by 12 transmembrane helices, and it functions as a homodimer, requiring interaction with glycosylated proteins like basigin for proper localization and function. MCT4's expression is regulated by hypoxia-inducible factors, making it a key player in cellular responses to hypoxic conditions. Alterations in SLC16A3 expression have been linked to various diseases, including cancer and neurodegenerative disorders, underscoring its significance in both normal physiology and pathological states (Halestrap2011The; Zhao2021Integrative; Choi2019Hypoxiainduced; Halestrap2013The).

## Structure
The SLC16A3 gene encodes the monocarboxylate transporter 4 (MCT4), which is part of the SLC16 solute carrier family. MCT4 is characterized by its structure comprising 12 transmembrane helices, with both the N- and C-termini located intracellularly, and a large intracellular loop between transmembrane segments 6 and 7 (Halestrap2011The; Halestrap2013The). This topology is typical of the major facilitator superfamily (MFS) fold, which is common among transport proteins (Bosshart2019Mechanistic).

MCT4 functions as a homodimer, which is indicative of its quaternary structure (Jansen2008Characterization). The protein requires association with glycosylated ancillary proteins, such as basigin, for proper localization and function at the plasma membrane (Halestrap2011The; Halestrap2013The). Although specific post-translational modifications of MCT4 are not detailed, the requirement for glycosylated partners suggests a role for glycosylation in its function.

The structural model of MCT1, a closely related transporter, provides insights into the potential structure of MCT4, as they share similar structural features (Halestrap2011The; Halestrap2013The). However, specific structural details unique to SLC16A3 are not extensively covered in the available literature.

## Function
SLC16A3 encodes the monocarboxylate transporter 4 (MCT4), which is primarily involved in the proton-linked transport of monocarboxylates such as L-lactate and pyruvate across the plasma membrane. MCT4 is predominantly active in glycolytic tissues, including white skeletal muscle fibers, astrocytes, and certain tumor cells, where it facilitates the efflux of lactic acid produced during glycolysis (Halestrap2011The; Meredith2008The). This transporter plays a crucial role in maintaining cellular pH and metabolic homeostasis by preventing the accumulation of lactic acid within cells, which could otherwise lead to acidosis (Halestrap2013The; Halestrap2004The).

MCT4 has a high Km for pyruvate, which ensures that pyruvate is retained within the cell for conversion to lactate, thus supporting continued glycolytic activity (Halestrap2011The; Halestrap2013The). The expression of MCT4 is upregulated under hypoxic conditions, mediated by hypoxia-inducible factor 1a (HIF-1a), which binds to hypoxia response elements in the MCT4 promoter (Halestrap2013The). This regulation is particularly important in tissues and cells that rely heavily on glycolysis for energy, such as during intense exercise or in rapidly proliferating tumor cells (Adijanto2012The; HALESTRAP1999The).

## Clinical Significance
Alterations in the expression of the SLC16A3 gene, which encodes the monocarboxylate transporter 4 (MCT4), have significant clinical implications in various diseases. In cancer, high expression of SLC16A3 is associated with poor prognosis and survival outcomes. In bladder cancer, particularly muscle-invasive bladder cancer (MIBC), elevated SLC16A3 expression correlates with poor overall survival and a poor response to platinum-based chemotherapy (Zhao2021Integrative). Similarly, in pancreatic cancer, increased SLC16A3 expression is linked to cancer progression and poor survival, suggesting its potential as a prognostic marker and therapeutic target (Yu2020Comprehensive).

In the context of neurodegenerative diseases, SLC16A3 expression is implicated in Alzheimer's disease (AD). In aged mice and AD models, an alternative splicing event involving intron retention in the SLC16A3 transcript has been observed, potentially affecting MCT4 protein synthesis and cellular metabolism. This splicing alteration may play a role in the progression of AD by impacting energy metabolism and lactate transport in the brain (ELSeedy2023Identification).

Overall, SLC16A3's role in lactate transport and its altered expression in various pathological conditions highlight its importance in disease mechanisms and potential as a therapeutic target.

## Interactions
SLC16A3, also known as monocarboxylate transporter 4 (MCT4), interacts with the glycoprotein CD147 (basigin), which is essential for its proper expression and localization on the cell surface. This interaction is crucial for the transport of lactate and other monocarboxylates across the plasma membrane. CD147 acts as a chaperone, facilitating the cell surface expression of MCT4, as well as MCT1, but not MCT2. This interaction has been demonstrated through co-immunoprecipitation and chemical cross-linking studies, which show that CD147 is tightly associated with MCT4, enhancing its function in lactate transport (Kirk2000CD147).

Under hypoxic conditions, the transcriptional regulation of SLC16A3 involves interactions with several transcription factors. FBI-1, encoded by ZBTB7A, represses SLC16A3 by binding to functional response elements (FREs) and hypoxia response elements (HREs) in its promoter. This repression is relieved under hypoxia as NF-κB (RelA/p65) downregulates ZBTB7A, allowing HIF-1α to activate SLC16A3 transcription. This regulatory mechanism affects lactate efflux and cell proliferation in hypoxic cancer cells, highlighting the role of SLC16A3 in cellular metabolism and survival (Choi2019Hypoxiainduced).


## References


[1. (ELSeedy2023Identification) Ayman EL-Seedy, Luc Pellerin, Guylène Page, and Veronique Ladeveze. Identification of intron retention in the slc16a3 gene transcript encoding the transporter mct4 in the brain of aged and alzheimer-disease model (appsweps1de9) mice. Genes, 14(10):1949, October 2023. URL: http://dx.doi.org/10.3390/genes14101949, doi:10.3390/genes14101949. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14101949)

[2. (HALESTRAP1999The) Andrew P. HALESTRAP and Nigel T. PRICE. The proton-linked monocarboxylate transporter (mct) family: structure, function and regulation. Biochemical Journal, 343(2):281–299, October 1999. URL: http://dx.doi.org/10.1042/bj3430281, doi:10.1042/bj3430281. This article has 809 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3430281)

[3. (Halestrap2004The) Andrew P. Halestrap and David Meredith. The slc16 gene family?from monocarboxylate transporters (mcts) to aromatic amino acid transporters and beyond. Pfl�gers Archiv European Journal of Physiology, 447(5):619–628, February 2004. URL: http://dx.doi.org/10.1007/s00424-003-1067-2, doi:10.1007/s00424-003-1067-2. This article has 823 citations.](https://doi.org/10.1007/s00424-003-1067-2)

[4. (Jansen2008Characterization) Sarah Jansen, Marie Pantaleon, and Peter L. Kaye. Characterization and regulation of monocarboxylate cotransporters slc16a7 and slc16a3 in preimplantation mouse embryos1. Biology of Reproduction, 79(1):84–92, July 2008. URL: http://dx.doi.org/10.1095/biolreprod.107.066811, doi:10.1095/biolreprod.107.066811. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1095/biolreprod.107.066811)

[5. (Meredith2008The) D. Meredith and H. C. Christian. The slc16 monocaboxylate transporter family. Xenobiotica, 38(7–8):1072–1106, August 2008. URL: http://dx.doi.org/10.1080/00498250802010868, doi:10.1080/00498250802010868. This article has 81 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/00498250802010868)

[6. (Halestrap2013The) Andrew P. Halestrap. The slc16 gene family – structure, role and regulation in health and disease. Molecular Aspects of Medicine, 34(2–3):337–349, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.05.003, doi:10.1016/j.mam.2012.05.003. This article has 519 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.05.003)

[7. (Adijanto2012The) Jeffrey Adijanto and Nancy J. Philp. The SLC16A Family of Monocarboxylate Transporters (MCTs)—Physiology and Function in Cellular Metabolism, pH Homeostasis, and Fluid Transport, pages 275–312. Elsevier, 2012. URL: http://dx.doi.org/10.1016/b978-0-12-394316-3.00009-0, doi:10.1016/b978-0-12-394316-3.00009-0. This article has 77 citations.](https://doi.org/10.1016/b978-0-12-394316-3.00009-0)

[8. (Yu2020Comprehensive) Shan Yu, Yanshuang Wu, Chunlong Li, Zhaowei Qu, Ge Lou, Xiaorong Guo, Jingjing Ji, Nan Li, Mian Guo, Maomao Zhang, Lei Lei, and Sheng Tai. Comprehensive analysis of the slc16a gene family in pancreatic cancer via integrated bioinformatics. Scientific Reports, April 2020. URL: http://dx.doi.org/10.1038/s41598-020-64356-y, doi:10.1038/s41598-020-64356-y. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-020-64356-y)

[9. (Bosshart2019Mechanistic) Patrick D. Bosshart, David Kalbermatter, Sara Bonetti, and Dimitrios Fotiadis. Mechanistic basis of l-lactate transport in the slc16 solute carrier family. Nature Communications, June 2019. URL: http://dx.doi.org/10.1038/s41467-019-10566-6, doi:10.1038/s41467-019-10566-6. This article has 83 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-10566-6)

[10. (Kirk2000CD147) P. Kirk, M.C. Wilson, C. Heddle, M.H. Brown, A.N. Barclay, and A.P. Halestrap. Cd147 is tightly associated with lactate transporters mct1 and mct4 and facilitates their cell surface expression. The EMBO Journal, 19(15):3896–3904, August 2000. URL: http://dx.doi.org/10.1093/emboj/19.15.3896, doi:10.1093/emboj/19.15.3896. This article has 519 citations.](https://doi.org/10.1093/emboj/19.15.3896)

[11. (Choi2019Hypoxiainduced) Seo-Hyun Choi, Min-Young Kim, Young-So Yoon, Dong-In Koh, Min-Kyeong Kim, Su-Yeon Cho, Kyung-Sup Kim, and Man-Wook Hur. Hypoxia-induced rela/p65 derepresses slc16a3 (mct4) by downregulating zbtb7a. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1862(8):771–785, August 2019. URL: http://dx.doi.org/10.1016/j.bbagrm.2019.06.004, doi:10.1016/j.bbagrm.2019.06.004. This article has 25 citations.](https://doi.org/10.1016/j.bbagrm.2019.06.004)

[12. (Halestrap2011The) Andrew P. Halestrap. The monocarboxylate transporter family—structure and functional characterization. IUBMB Life, 64(1):1–9, November 2011. URL: http://dx.doi.org/10.1002/iub.573, doi:10.1002/iub.573. This article has 529 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/iub.573)

[13. (Zhao2021Integrative) Yang Zhao, Bin Zhao, Wei-Hua Yan, Yan Xia, Zhi-Hui Wang, Guo-Yang Zheng, Wen-Da Wang, and Yu-Shi Zhang. Integrative analysis identified mct4 as an independent prognostic factor for bladder cancer. Frontiers in Oncology, August 2021. URL: http://dx.doi.org/10.3389/fonc.2021.704857, doi:10.3389/fonc.2021.704857. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.704857)